Q-omics provides the consensus-scored RPL21P109 profile across patient tissues and cancer cell-line models. RPL21P109 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, RPL21P109 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, RPL21P109 RNA expression shows 6,959 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight OV, KIRC, and CCRCC as cancer lineages where RPL21P109 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL21P109 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL21P109 survival associations across molecular data types. RPL21P109 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL21P109 RNA expression–survival associations across cancer types. High RPL21P109 expression shows unfavorable associations in OV, DLBC, ESCA, UCEC and GBM, but favorable associations in LUSC. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify OV as the clearest survival context for RPL21P109 RNA expression.
This table summarizes RPL21P109 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL21P109. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL21P109 shows lower tumor expression in KIRC and higher tumor expression in BRCA. The KIRC box plot shows higher RPL21P109 RNA expression in normal versus tumor tissue (log2 FC = −0.023, t-test p = .030).
This table shows molecular features associated with RPL21P109 in patient tissues and cancer cell lines. In patient samples, RPL21P109 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
